4/A: Bios Equity COF, LP Amends Form 4 Filing to Correct Price Reporting in Actuate Therapeutics Transaction

Bios Equity COF, LP files an amendment to its Form 4, correcting the price reported in a previous filing related to transactions in Actuate Therapeutics, Inc. (ACTU) common stock following the company's IPO.

Summary

• Bios Equity COF, LP filed an amended Form 4 with the SEC to correct the price reported in column 4 of Table I in the original Form 4.
• The amendment relates to transactions involving Actuate Therapeutics, Inc. (ACTU) common stock.
• The original Form 4 was filed on August 14, 2024, and the amendment is dated August 20, 2024.
• The corrected filing pertains to the automatic cashless exercise of warrants in connection with Actuate Therapeutics' IPO on August 12, 2024.
• The warrants were exercised at a price of $5.27 per share.
• The amendment does not report any new transactions; it solely corrects the price information.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing (Form 4 amendment) to correct a price error. It doesn't contain any information that would significantly impact investor sentiment positively or negatively. The sentiment is neutral to slightly positive as it shows attention to detail and compliance.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, including directors and significant shareholders. Amendments are filed to correct errors or omissions in previous filings, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• The correction of the price information ensures accurate reporting to shareholders and the public.

Key Dates